Pharmacokinetics of the time-dependent elimination of all-trans-retinoic acid in rats

AAPS Journal

Volumn 6, Issue 1, 2004, Pages

  Saadeddin, Anas ^a   Torres Molina, Francisca ^a   Cárcel Trullols, Jaime ^a   Araico, Amparo ^a   Peris, José Esteban ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

All trans retinoic acid; intravenous administration; Oral administration; Pharmacokinetic model; rat; Time dependent elimination

Indexed keywords

RETINOIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG METABOLISM; DRUG RESISTANCE; DRUG SCREENING; EXPERIMENTAL MODEL; HYPOTHESIS; IN VIVO STUDY; INTERMETHOD COMPARISON; MALE; METABOLIC INHIBITION; NONHUMAN; RAT; SINGLE DRUG DOSE; STEADY STATE; TIME;

EID: 34248671958     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps060101     Document Type: Article

References (24)

1. Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene. 2001;20:7140-7145.
2. Fenaux P, Chomienne C, Degos L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol. 2001;38:13-25.
3. Reynolds CP, Lemons RS. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am. 2001;15:867-910.
4. Camacho LH. Clinical applications of retinoids in cancer medicine. J Biol Regul Homeost Agents. 2003;17:98-114.
5. Conley BA, Egorin MJ, Sridhara R, et al. Van echo DA. Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother Pharmacol. 1997;39:291-299.
6. Reynolds CP. Differentiating agents in pediatric malignancies: retinoids in neuroblastoma. Curr Oncol Rep. 2000;2:511-518.
7. Todesco A, Carli M, Iacona I, Frascella E, Ninfo V, Rosolen A. All-trans retinoic acid and interferon-alpha in the treatment of a patient with resistant metastatic osteosarcoma. Cancer. 2000;89:2661-2666.
8. Goncalves A, Camerlo J, Bun H, et al. Phase II study of a combination of cisplatin, all-trans-retinoic acid and interferon-alpha in squamous cell carcinoma: clinical results and pharmacokinetics. Anticancer Res. 2001;21:1431-1437.
9. Goldberg JS, Vargas M, Rosmarin AS, et al. Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma. Cancer. 2002;95:1220-1227.
10. Adamson PC, Bailey J, Pluda J, et al. Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol. 1995;13:1238-1241.
11. Adamson PC, Reaman G, Finklestein JZ, Feusner J, Berg SL, Blaney SM. O'brien M, Murphy RF, Balis, FM. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. J Clin Oncol. 1997;15:3330-3337.
12. Regazzi MB, Iacona I, Gervasutti C, Lazzarino M, Toma S. Clinical pharmacokinetics of tretinoin. Clin Pharmacokinet. 1997;32:382-402.
13. Gallagher RE. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia. 2002;16(10):1940-1958.
14. Torres-Molina F, Peris JE, Garcia-Carbonell MC, Aristorena JC, Granero L, Chesa-Jimenez J. Use of rats chronically cannulated in the jugular vein and the duodenum in pharmacokinetic studies. Effect of ether anesthesia on absorption of amoxicillin. Arzneimittelforschung. 1996;46:716-719.
15. Wagner JG. Pharmacokinetic absorption plots from oral data alone or oral/intravenous data and an exact Loo-Riegelman equation. J Pharm Sci. 1983;72:838-842.
16. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker Inc; 1982.
17. Pharsight Corporation Winnonlin. Professional ed 2.1. Pharsight Corporation, 299 California Avenue, Palo Alto, CA; 1998.
18. SPSS for Windows [computer program]. Release 10.0.5, standard version. Chicago, Illinois: SPSS Inc; 1999.
19. el Mansouri S, Tod M, Leclerq M, Petitjean O, Perret G, Porthault M. Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). Drug Metab Dispos. 1995;23:227-231.
20. Adamson PC, Balis FM, Smith MA, Murphy RF, Godwin KA, Poplack DG. Dose-dependent pharmacokinetics of all-trans-retinoic acid. J Natl Cancer Inst. 1992;84(17):1332-1335.
21. Adamson PC. Pharmacokinetics of all-trans retinoic acid: clinical implications in acute promyelocytic leukemia. Semin Hematol. 1994;31:14-17.
22. Wang Y, Zolfaghari R, Ross AC. Cloning of rat cytochrome P450RAI (CYP26) cDNA and regulation of its gene expression by all-trans-retinoic acid in vivo. Arch Biochem Biophys. 2002;401:235-243.
23. Ozpolat B, Lopez-Berestein G, Admason P, Fu CJ, Williams AH. Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers. J Pharm Pharm Sci. [serial online]. 2003;6:292-301. Available at: www.ualberta.ca/~csps. Accessed October 22, 2003.
24. Lampen A, Meyer S, Nau H. Effects of receptor-selective retinoids on cyp26 gene expression and metabolism of all-trans-retinoic acid in intestinal cells. Drug Metab Dispos. 2001;29:742-747.